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Abstract: Diabetes is associated with a mitochondrial dysfunction. Hyperglycaemia is also 
clearly recognized as the primary culprit in the pathogenesis of cardiac complications. In 
response  to  glycation  and  oxidative  stress,  cardiac  mitochondria  undergo  cumulative 
alterations, often leading to heart deterioration. There is a continuous search for innovative 
treatment strategies for protecting the heart mitochondria from the destructive impact of 
diabetes. Aminoguanidine derivatives have been successfully used in animal model studies 
on  the  treatment  of  experimental  diabetes,  as  well  as  the  diabetes-driven  dysfunctions  
of  peripheral  tissues  and  cells.  Considerable  attention  has  been  paid  particularly  to  
β-resorcylidene aminoguanidine (RAG), often shown as the efficient anti-glycation and 
anti-oxidant agent in both animal studies and in vitro experiments. The aim of the present 
study was to test the hypothesis that RAG improves oxidative phosphorylation and electron 
transport  capacity  in  mitochondria  impaired  by  hyperglycaemia.  Diabetes  mellitus  was 
induced in Wistar rats by a single intraperitoneal injection of streptozotocin (70 mg/kg 
body  weight).  Heart  mitochondria  were  isolated  from  healthy  rats  and  rats  with 
streptozotocin-diabetes. Mitochondrial respiratory capacity was measured by high resolution 
respirometry  with  the  OROBOROS  Oxygraph-2k  according  to  experimental  protocol 
including respiratory substrates and inhibitors. The results revealed that RAG protects the 
heart against diabetes-associated injury by improving the mitochondrial bioenergetics, thus 
suggesting a possible novel pharmacological strategy for cardioprotection. 
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1. Introduction 
Recent  studies  have  shown  that  one  of  the  major  consequences  of  diabetes  mellitus  is  the 
development of diabetic cardiomyopathy. Cardiovascular disease is the leading cause of death in the 
diabetic population. Cardiac dysfunction is common in diabetics regardless of risk factors for coronary 
artery  disease  and  hypertension  [1].  Emerging  evidence  suggests  that  diabetic  cardiomyopathy  is 
linked to alterations in myocardial fuel and energy metabolism. Different experimental data indicate 
that the mitochondrion is one of the main sites implicated in the development of cardiac dysfunction. 
Because mitochondria are the main cellular source of ATP, attention has been paid to understanding  
the causes of the decrease in mitochondrial respiratory function and the effect of the resulting decrease 
in  ATP  production  on  cardiac  contractility  and  hemodynamics.  Disruption  of  the  mitochondrial 
respiratory function is regarded as a key factor in the development of pathologic complications in heart 
and other tissues under diabetic conditions [2]. Therefore, mitochondrial damage has been proposed as 
a central mediator in the development of diabetes complications. A number of reports have provided 
evidence  for  alteration  in  the  respiratory  activity  of  mitochondria  isolated  from  different  diabetic 
tissues including liver, heart, skeletal muscle and kidney. However, the consensus is not univocal as 
discrepant and often contradictory  results in mitochondrial functions of diabetic tissues have been 
reported  by  different  groups.  It  has  been  suggested  that  the  decrease  in  mitochondrial  respiration 
observed in diabetic tissues is due to a decrease in the electron transport chain activity. This decrease 
has been attributed to defects in several active sites of the mitochondrial electron transport chain, 
including all mitochondrial complexes (I, II, III, IV, and the ATP synthase) [3].  
To understand the physiological and pathological changes of this complex disease, animal models 
of diabetes are important research tools, since animal studies allow for tight control over experimental 
conditions, which is almost impossible to achieve in human populations. 
In the present study,  we used STZ-induced rats  as type 1 diabetes mellitus model. STZ-induced 
diabetic rats, commonly used as an animal model of type 1 diabetes mellitus, are obtained after selective 
destruction of β-cell by streptozotocin (STZ), a broad spectrum antibiotic, with diabetogenic effects. 
STZ-injected  rats  present  many  characteristics  seen  in  insulin-dependent  diabetic  human  patients: 
hypoinsulinemia, hyperglycaemia, ketonuria, and hyperlipidaemia. Therefore, this model is of great 
use to evaluate the changes promoted by uncontrolled type 1 diabetes [4].  
For our study, we focused on the heart and, in particular on cardiac mitochondria. Heart in rats with 
acute  streptozotocin-induced  diabetes  is  characterized  by  altered  metabolism  and  alterations  in 
respiration and phosphorylation rates. Consequently, even small changes observed in the mitochondrial 
functionality can disturb the production of ATP. The loss of this valuable fuel for the heart is dangerous Int. J. Mol. Sci. 2011, 12                       
 
8015
and can be cause of serious heart complications. Therefore, there is a continuous search for innovative 
treatment strategies for protecting the heart mitochondria from destructive impact of diabetes. The 
potential application of some agents to reduce glycation phenomenon and to increase the protective 
defense system by targeting mitochondria is very important.  
In  our  opinion  the  role/activity  of  such  compound  could  be  fulfilled  by  β-resorcylidene 
aminoguanidine  (RAG).  Thus,  the  aim  of  the  present  study  was  to  test  the  hypothesis  that  RAG 
improves  oxidative  phosphorylation  and  electron  transport  capacity  in  mitochondria  impaired  by 
hyperglycaemia. Aminoguanidine and its derivatives have been shown to inhibit AGE formation due 
to  their  reaction  with  carbonyl  products  that  are  formed  during  the  end  phases  of  non-enzymatic 
protein glycation, both in vitro and in vivo [5,6]. Nevertheless, the mechanism of RAG action is not 
understood precisely. Some data evidence that administration of RAG to diabetic rats (Wistar rats, 
RAG used at the dose of 10 mg·kg
–1 by stomach probe, once daily for 8 weeks) decreases the level of 
AGE products (advanced glycation end products), glucose and triacylglycerols level, and the level of 
glycated HbA1c which take part in the development of post-diabetic complications in subjects suffering 
from  diabetes  [7].  Some  other  studies  revealed  that  RAG  acts  as  anti-oxidant  and  possesses 
antimutagenic and bacteriostatic properties [8].  
Based  on  the  above  considerations,  we  have  decided  to  check  the  impact  of  RAG  on  heart 
mitochondrial respirometric states believing that RAG is able to protect the mitochondrial bioenergetics 
against harmful effect of hyperglycaemia. To test this assumption, we used a streptozotocin diabetic rat 
model  to  examine  the  mitochondrial  oxygen  consumption  as  an  index  of  mitochondrial  respiratory 
function over a time course of 12 weeks of diabetes. The following specific aims were realized: (1) the 
determination of the level of ADP-coupled state respiration (STATE 3 or STATE P) as an index of the 
oxygen amount utilized on ATP production measured at saturating concentrations of ADP and Pi. In 
other words it is an assessment of the capacity of the coupled oxidative phosphorylation (OXPHOS 
capacity)  at  the  physiological  ATP  concentration;  (2)  the  estimation  of  the  level  of  STATE  4 
respiration (state in the absence of ADP) as an index of mitochondrial condition/integrity after ATP 
production; (3) the evaluation of the FCCP-stimulated respiration (state E, uncoupled) as an index of 
the capacity of the respiratory electron transport system capacity (ETS); (4) the definition of the RCR 
(Respiratory Control Ratio) as an index of the mitochondrial capacity oxygen flux in the presence of 
ADP; (5) the designation of the LEAK Control Ratio as an index of mitochondrial uncoupling or 
mitochondrial dyscoupling at constant ETS capacity; (6) the valuation of the Phosphorylation System 
Control Ratio as an index of the limitation of OXPHOS capacity (State P) by the phosphorylation 
system; and (7) the assessment of the ADP/O flux ratio (nmol ADP/nAtm O) as an index of the 
amount of ADP utilization per 1 atom of oxygen [9]. The elucidation of these main points helped us to 
assess the general effect of RAG on rat heart mitochondria isolated from tested animal groups as 
described below.  
2. Results and Discussion 
The effect of STZ-diabetes (12 weeks) and subsequent treatment with RAG (40 mg/kg) on the 
blood glucose level and selected respiratory parameters in hearts isolated from the male Wistar rats are 
detailed  in  Tables  1  and  2  and  Figures  1–4.  It  was  shown  that  RAG  supplementation  effectively Int. J. Mol. Sci. 2011, 12                       
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reduces the glycaemia level compared to glucose level measured in animals with non-treated diabetes. 
Nevertheless, this limitation in this parameter does not reach the glycaemic condition characteristic for 
healthy rats (Table 1).  
Table 1. The impact of β-resorcylidene aminoguanidine (RAG) on glucose level in tested 
animal groups. 
Parameter 
(mg%) 
Healthy Rats 
Healthy Rats 
+RAG 
Diabetic Rats 
Diabetic Rats 
+RAG 
p 
Glucose level 
in blood 
114.5 
(102; 111.75) 
107 
(103.5; 114.5) 
536.5 
(415.25; 674.25) 
403.5 
(362.25; 440.75) 
* 0.024 
Data were expressed as median and lower-upper quartile range; * p = 0.024 for “diabetic rats” 
compared to “diabetic rats + RAG”. 
Table 2. Changes in the heart mitochondria respiratory states in tested animal groups. 
Parameter  Healthy Rats 
Healthy Rats 
+RAG 
Diabetic Rats 
Diabetic Rats 
+RAG 
p 
State 3 
838.25  914.15  400,72 *  873.91 
* <0.001 
(629.09; 1089.71)  (731.25; 1105.87)  (351.77; 489.76)  (645.48; 1078.19) 
State 4 
309.21  329.85  179.91 *  287.88 
* <0.001 
(275.02; 343.41)  (276.83; 363.55)  (168.18; 196.86)  (259.24; 327.95) 
State E 
1067.23  1086.07  529.31 *  968.05 
* <0.001 
(908.23; 1244.42)  (903.13; 1147.72)  (414.27; 694.17)  (915.62; 1114.11) 
Data  were  expressed  as  median  and  lower-upper  quartile  range;  *  p  <  0.001  for  diabetic  rats 
compared to the other animal groups; States: 3, 4 and E were measured as (pmol O2 × s
−1 × cm
−3); 
For experimental details see “Experimental Methods”. 
Figure 1. RCR (Respiratory Control Ratio) of rat heart mitochondria isolated from healthy 
and diabetic rats as well as from rats supplemented with RAG (40 mg/kg). Data presented 
as median and upper-lower quartile range, n = 12–17 animals. Significance of differences 
estimated  by  means  of  Kruskal–Wallis  and  median  tests  and  post  hoc  all-pairwise 
comparisons  Connover–Inman  test:  diabetic  rats  vs.  all  other  tested  animal  groups:  
* p < 0.0001. For experimental details see “Experimental Methods”. 
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Figure 2. L/E (Leak Control Ratio) of rat heart mitochondria isolated from healthy and 
diabetic rats as well as from rats supplemented with RAG (40 mg/kg). Data presented as 
median and upper-lower quartile range, n = 12–17 animals. Significance of differences 
estimated  by  means  of  Kruskal–Wallis  and  median  tests  and  post  hoc  all-pairwise 
comparisons  Connover–Inman  test:  diabetic  rats  vs.  all  other  tested  animal  groups:  
* p < 0.0001. For experimental details see “Experimental Methods”. 
 
Figure 3. P/E (Phosphorylation System Control Ratio) of rat heart mitochondria isolated 
from healthy and diabetic rats as well as from rats supplemented with RAG (40 mg/kg). 
Data presented as median and upper-lower quartile range, n = 12–17 animals. Significance 
of differences estimated by one-way ANOVA and post hoc Tukey-Kramer test: diabetic 
rats  vs.  all  other  tested  animal  groups:  *  p  <  0.001.  For  experimental  details  see 
“Experimental Methods”. 
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Figure 4. ADP/O ratio of rat heart mitochondria isolated from healthy and diabetic rats as 
well  as  from  rats  supplemented  with  RAG  (40  mg/kg).  Data  presented  as  median  and 
upper-lower quartile range, n = 12–17 animals. Significance of differences estimated by 
one-way ANOVA and post hoc Tukey-Kramer test: diabetic rats vs. all other tested animal 
groups: * p < 0.001. For experimental details see “Experimental Methods”. 
 
It may be seen that the significant decrease in such tested mitochondrial respirometric states as: 
state 3, state 4, state E and in the parameters such as RCR and ADP/O and increase in L/E and P/E 
parameters  were  revealed.  These  results  confirmed  that  long-fasting  (3  months)  and  not-treated 
diabetes affects the heart mitochondria bioenergetics. The observed changes in the main parameters of 
mitochondrial respiration would consequently lead to the limitation in ATP production and probably to 
the increase in the ROS formation. However, the diabetes-induced mitochondria changes are well 
described [4,10,11], therefore the main aim of this paper was not the confirmation of the results well 
known  for  a  long  time  but  the  using  RAG  as  the  anti-diabetic  drug  in  the  experimental  diabetes 
treatment and checking whether RAG is able to reduce the negative effect of diabetes on mitochondrial 
bioenergetics. We have focused our attention on the most important mitochondrial parameters such as 
state 3, state 4, state E and other ones such as RCR ratio, L/E ratio, P/E ratio or ADP/O flux ratio. All 
these  parameters  were  measured  as  described  under  “Experimental  Methods  in  the  Section  3.4 
Mitochondrial Respiratory Measurements”. Our results clearly indicate that RAG used in a dose of 
40 mg/kg  and  administrated  for  3  months  of  treatment  efficiently  protects  mitochondria  from  the 
adverse impact of diabetes. It has been reported that RAG rather does not allow for the development of 
the harmful effect of diabetes on mitochondria than restores the functioning of mitochondria to the 
condition typical for healthy animals (Table 2 and Figures 1–4). Heart mitochondria isolated from 
diabetic subjects showed significantly depressed states 3, 4 and state E relative to hearts of diabetic 
subjects supplemented with RAG. These data (Table 2) indicate that diabetic mitochondria respire in a 
slower manner and consequently other processes related to mitochondrial respiratory are inhibited.  
As shown in Figure 1, RCR ratio, which gives the information about the state of mitochondrial 
coupling, is significantly reduced for diabetic mitochondria compared to those isolated from the other Int. J. Mol. Sci. 2011, 12                       
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tested animal groups (healthy rats; healthy rats supplemented with RAG and diabetic rats supplemented 
with RAG). 
Leak control ratio (L/E) was used to assess the state of mitochondrial uncoupling. As shown in 
Figure  2,  L/E  ratio  significantly  increased  only  for  diabetic  mitochondria  as  compared  to  other 
mitochondrial preparations (p < 0.0001). These results clearly indicate that diabetic mitochondria were 
partly  uncoupled  after  the  3  months  of  diabetes.  Nevertheless,  the  exposure  to  RAG  successfully 
protected the heart mitochondria against STZ-diabetes.  
Another parameter, Phosphorylation System Control ratio (P/E) let us observe the impact of the 
phosphorylation system on the OXPHOS capacity in functioning mitochondria. If the value of this  
ratio is about 1, this means that the mitochondrial respiration is fully inhibited. In the case of our study, 
only for diabetic mitochondria we have observed a significant increase in the value of this parameter 
(median = 1,045; p = 0.000137), (Figure 3).  
The last measured parameter was ADP/O ratio which informs about the amount of ATP produced 
per total oxygen consumed by mitochondria. As shown in Figure 4, diabetic mitochondria produced less 
ATP than other tested mitochondria. For diabetic mitochondria isolated from animals supplemented with 
RAG, the value of ADP/O is similar to this one received for mitochondria isolated from healthy rats.  
It  clearly  indicates  that  diabetes  has  not  affected  the  mitochondrial  functionality  in  this  group  of  
tested animals.  
To summarize, our results strongly suggest that diabetic mitochondria present some mitochondrial 
dysfunctions while diabetic mitochondria derived from RAG-treated animal group possess all tested 
parameters  at  the  level  characteristic  for  healthy  rats.  This  in  vivo  experiment  showed  that  RAG 
treatment can be effective in reduction of mitochondrial dysfunction observed in diabetic subjects.  
However,  at  this  stage  is  not  clear  if  similar  situation  could  occur  in  humans  suffering  from 
mitochondrial disturbances during the course of this disease. More, we even cannot be sure that after 
the next in vivo study (in the same experimental conditions) we have a chance to obtain the same (or at 
least similar) results. It was well documented in the paper of Mujkosova et al. that seasonal differences 
in the heart activity are observed. Their results revealed that values of mitochondrial heart Mg
2+-ATPase 
activity  in  the  winter/spring-period  (W/S-P)  exceeded  significantly  (p  <  0.05–0.001)  those  in  the 
summer/autumn-period (S/A-P). A similar trend was also observed in hearts of animals with acute  
(8 days) streptozotocin diabetes. Such results indicate that seasonal differences may play a decisive 
role in the evaluation of properties and function of rat heart mitochondria [12]. It is also worth noting 
that seasonal changes can modify the effect of the tested compound. Therefore our promising results 
describe in this paper require further research and further confirmations.  
Our data are not the first which indicate that RAG could be successfully used in the anti-diabetic 
treatment. Previously, the studies of Waczulikova et al. revealed that RAG possesses inhibitory activity 
in the process of the non-enzymatic glycation and oxidation of proteins [13]. RAG induced in vivo a 
significant  diminution  of  glycated  proteins  and  an  increase  in  the  fluidity  of  cardiac  sarcolemma, 
consequently, it resulted in the normalization of an increased malondialdehyde level in kidney tissue in 
rats with streptozotocin-induced diabetes [14]. 
As for the RAG effect on functioning of mitochondria, we suggest that activity of RAG strictly 
depends  on  the  used  concentration/dose.  So  far,  only  one  paper  [15]  describes  the  mitochondrial 
bioenergetic  upon  exposure  to  RAG  activity.  In  our  previous  research  [15],  we  monitored  the Int. J. Mol. Sci. 2011, 12                       
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mitochondrial  membrane  potential,  membrane  fluidity  and  the  respiration  capacity  in  rat  liver 
mitochondria  isolated  from  Wistar  rats  in  the  in  vitro  system.  RAG  was  used  at  three  selected 
concentrations: 50, 100 and 200 µM. Then, our findings revealed that RAG had the ability to: fluidize 
a mitochondrial lipid bilayer, cause a depolarization of mitochondrial membrane and limit oxygen 
consumption  by  mitochondria.  Surprisingly,  these  data  have  revealed  that,  regardless  of  the  used 
concentration, RAG does not influence the respiratory chain of mitochondria under the conditions of 
state  4.  Thus,  we  were  unable  to  parallel  the  depolarization  and  fluidizing  activity  of  RAG  by 
alterations  in  mitochondrial  respiratory  function.  Nevertheless,  in  samples  with  ADP-supported 
respiration (state 3), we observed the slight but significant limitation of mitochondrial respiration at 
higher RAG concentrations of 100–200 µM. These results, on one hand, showed that the changes in the 
structure of mitochondrial membrane are evidently not sufficient to significantly impair the transport  
of electrons through complexes of respiratory chain. On the other side, we argued that RAG could 
contribute to the reduced transformation of ADP to ATP, as evidenced in that paper. These in vitro 
studies have led to the conclusion that RAG may affect mitochondrial function, and thus, it may have an 
impact on the overall image of impaired physiology under some experimental pathological conditions.  
In this paper, we demonstrate that RAG can be successfully used in the animal model of experimental 
diabetes. We have not only confirmed the beneficial use of RAG in diabetes-induced pathology but we 
have also proved that, upon RAG treatment, heart mitochondria can be protected from the injurious 
effect of glucose excess in organism. As it was shown, no significant differences in the mitochondrial 
parameters were found between healthy rats and diabetic ones supplemented with RAG. This suggests 
that  RAG  seems  to  be  a  drug  that  can  eliminate  the  negative  effect  of  hyperglycaemia  on  heart 
mitochondria function if used in a proper dosage. In 2002, Liptakova et al., used RAG (10 mg/kg, 
8 weeks) in order to study its impact on antioxidant level in plasma and the liver, lipid oxidation and 
selected biochemical parameters (glucose level, glycated Hb, fructosamine, cholesterol, etc.) in Wistar 
healthy rats as well as in rats with STZ-induced diabetes [7]. The received data showed that RAG 
administration has not improved the antioxidant status in diabetic subjects and had a moderate effect 
on  the  reduction  of  such  glycation  markers  as  glycated  hemoglobin  or  fructosoamine.  From  our  
point of view, it is highly probable that RAG was applied at the too low dose in order to reveal its  
anti-glycation (or its anti-oxidant) activity. Moreover, our hypothesis concerning the appropriate usage 
of dose in the in vivo studies is partly evidenced by the study by Watala et al. The Authors applied 
RAG at the dose of 4 mg/kg in the model of experimental diabetes (Wistar rats) and found that, as a 
result  of  RAG  administration  (60  days),  neither  “early”  protein  glycation  products  nor  advanced 
glycation end-products were considerably affected. Farther, at the used dose, chronic RAG treatment 
did  not  significantly  inhibit  plasma  protein  glycation  in  STZ-diabetic  rats  and  blood  platelet 
fructosamine. Furthermore, although they demonstrated a tendency that RAG reduced AGEs in blood 
plasma proteins, this reduction remained beyond statistical significance. In addition to these results, the 
Authors have found that RAG possesses the antithrombotic activity and therefore can be useful to treat 
diabetic complications [16].  
However, the selection of an appropriate dose useful for pre-clinical as well as clinical studies is not 
an easy challenge. Speaking strictly in terms of significance, in vivo implications are not so clear 
because the effect of size cannot be quantitatively specified at the level of single cells, i.e., in in vitro 
investigation. Therefore, the choice of the “well-working” dose for in vivo studies can be tested for a Int. J. Mol. Sci. 2011, 12                       
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long time. Based on our findings, we suppose that RAG should be used at a dose higher than 10 mg/kg 
if we want to observe its anti-diabetic activity.  
3. Experimental Methods 
3.1. Chemicals 
RAG (β-resorcylidene  aminoguanidine.HCl; C8H10O2N4·HCl) has been synthesized as described 
elsewhere [15]. Briefly, the synthesis of RAG involved a simple condensation reaction. An equimolar 
amount of resorcylaldehyde was mixed with aminoguanidine hydrogen  carbonate. The reaction  was 
performed in ethanol/water (1:1, v/v ratio), and the reaction conditions were optimized with concentrated 
hydrochloric acid. After a short time, a crystalline precipitate of RAG chloride was formed. All other 
reagents and solvents used were of the highest analytical reagent grade and were purchased from 
Sigma (St. Louis, MO, USA). 
3.2. RAG Supplementation—In Vivo Experimental Design 
Seventy male rats of Wistar strain weighing approximately 250–300 g were used in this experiment. 
Before  the  commencement  of  the  experiment,  the  animals  were  acclimatized  to  the  laboratory 
conditions for a period of 2 weeks. They were maintained at an ambient temperature of 25 °C and 
12/12 h of light/dark cycle. Animals were given standard commercial rat chow and water ad libitum 
and  were  housed  under  standard  environmental  conditions  until  treatment  or  sacrifice.  The 
experiments  were  conducted  in  accordance  with  the  Guide  for  the  Care  and  Use  of  Laboratory 
Animals published by the US National Institute of Health (NIH Publication No. 85–23, revised 1985), 
as well as with the guidelines formulated by the European Community for the Use of Experimental 
Animals (L358-86/609/EEC) and the Guiding Principles in the Use of Animals in Toxicology (1989). 
All experiments were carried out under approval of an appropriate institutional local ethics committee. 
The  experimental  animals  were  randomly  divided  into  four  groups:  2  groups—each  of  them 
including healthy animals (2 × 15 rats) and further 2 groups—each of them including animals with 
STZ-induced diabetes (2 × 20 rats).  
Finally there were the following experimental groups:  
(1) healthy rats (non-diabetic) that received only fresh water;  
(2) RAG control group—healthy animals that were given RAG (ad libitum in water) in a dose of 
40 mg/kg, once daily for 12 weeks;  
(3) diabetic rats—animals with streptozotocin-induced diabetes that received only fresh water;  
(4) treated group—animals with streptozotocin-induced diabetes that were given RAG (ad libitum 
in water) in a dose of 40 mg/kg, once daily for 12 weeks;  
Diabetes was induced by an intraperitoneal injection of streptozotocin (STZ, dissolved in 0.1 mol/L 
citrate buffer, pH 4.5) in a dose of 70 mg/kg body weight. Diagnosis of diabetes was made on the basis 
of the non-fasting blood glucose concentration (measured in the morning hours, 08:00–10:00 AM). 
The animals with blood glucose concentrations higher than 16.7 mmol/L, were considered diabetic and 
included to the study. Each STZ-injected rat showing hyperglycaemia lower than 16.7 mmol/L at 72 h Int. J. Mol. Sci. 2011, 12                       
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after injection was excluded from the study. The experiment on RAG effect (administered at a daily 
dose  of  40  mg/kg)  started  after  7  days  upon  induction  of  laboratory  confirmed  diabetes.  At  the 
termination of the experiment the survivors in both groups were sacrificed and their blood and organs 
were collected for further biochemical analyses.  
3.3. Blood Collection and Glucose Level Determination 
In-life non-fasting blood glucose (measured always at 09:00–10:00 AM) was measured once in 
control non-diabetic animals and monitored weekly in all STZ diabetic animals under study. Blood 
was obtained from tail vessels by needle prick and tested using glucose strips or, when exceeding 
600 mg%, with biochemical analyzer. The last determination of blood glucose was recorded at time 
preceding the critical event (within a week) and referred respectively to as terminal glucose. 
3.4. Isolation of Rat Heart Mitochondria 
Mitochondria  were  isolated  according  to  the  procedure  of  Ferko  et  al.,  with  small  
modifications  [10].  Briefly,  hearts  damped  with  small  volume  of  ice-cold  isolation  solution  (IS, 
containing in mmol/L: 250 mM sucrose, 0.5 mM EDTA, 10 Mm Tris and 1 g/L bovine serum albumin, 
pH = 7.4) were cut into small pieces with scissors and left together with 10 mL of IS containing the 
addition of dispase II (Sigma D 4693) 2.5 mg/g wet wt. (heart) on 10 min. Then, the pieces of heart 
were  then  transferred  to  a  teflon/glas  homogenizer  and  homogenized  gently  for  2–3  min.  After 
centrifugation of homogenate at 800× g for 10 min (4 °C) the protease containing supernatant together 
with  a  part  of  mitochondria  which  were  in  a  direct  contact  with  the  protease,  was  centrifuged  at  
4800×  g,  10  min,  4  °C.  Then,  the  pellet  was  resuspended  in  the  same  volume  of  IS  but  without 
protease, again homogenized (4800× g, 10 min, 4 °C) and spun down as previously described. The last 
centrifugation of pellet was done at the same conditions describe above. Finally, the pellet containing 
rat  mitochondria  was  again  resuspended  in  the  ice-cold  isolation  solution  (IS  buffer,  pH  7.4). 
Mitochondrial protein content was determined by the Bicinchoninic Acid Kit. 
3.5. Mitochondrial Respiratory Measurements 
Oxygen consumption of isolated mitochondria was determined polarographically at 37 °C with a 
Clark  oxygen  electrode,  connected  to  a  high  resolution  respirometry  (OROBOROS,  Oxygraph, 
Innsbruck, Austria) in a closed chamber with a magnetic stirring. The oxygen consumption rates were 
calculated  as  the  time  derivative  trace  (DatLab  software  for  data  acquisition  and  analysis, 
OROBOROS
®).  The  respiration  medium  consisted  of  110  mM  sucrose,  60  mM  K-lactobionate, 
0.5 mM  EGTA,  1  g/liter  BSA  essentially  fatty  acid  free,  3  mM  MgCl2,  20  mM  taurine,  10  mM 
KH2PO4, 20 mM HEPES adjusted to pH 7.1 at 37 °C (buffer called MIR05) and catalase (280 IU/mL) 
(obtaining so called MIR06 buffer) was used [17]. The medium was equilibrated for 30 to 40 min with 
air in the oxygraph chambers and stirred at 540 to 560 rpm until a stable signal was obtained for 
calibration at air saturation. 
The  corresponding  oxygen  concentration  was  calculated  from  the  digitally  recorded  barometric 
pressure and the oxygen solubility at 37 °C. The amplified signal was recorded on a computer with Int. J. Mol. Sci. 2011, 12                       
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online display of the calibrated oxygen concentration and oxygen flux (negative time derivative of 
oxygen  concentration).  Instrumental  background  flux  was  measured  in separate  controls  using  the 
same medium without biological material. 
Respirometric regime: isolated rat heart mitochondria (0.175 mg of protein/mL for each measurement 
of respiration) and respiratory substrate for complex II/respiratory inhibitor for complex I—succinate  
(10 mM)/rotenone (0.5 µM) were added to the standard respiration medium—MIR06 (2 mL). Further, 
the  respirometric  states  were  induced  by  addition  of  substrates  for  electron  input  into  a  specific 
respiratory complex (state 2: respiration remains slow, mainly compensating for the passive proton 
leak and inner membrane ion channels such as uncoupling proteins or the permeability transition pore), 
and finally titration of a low but saturating concentration of ADP (state 3: respiration is activated by 
the back-flow of protons into the matrix through the ATP synthase and the concomitant partial drop of 
the electrochemical proton gradient across the inner mitochondrial membrane). After exhaustion of 
ADP  (0.25  mM)  which  is  phosphorylated  to  ATP,  respiration  returns  to  a  resting  level  (state  4: 
elevated above state 2 if ATPase activity recycles ATP to ADP). FCCP-uncoupled respiration was 
performed by adding 1.5–2 µM of FCCP (carbonyl cyanide p-trifluoromethoxyphenylhydrazone) to 
mitochondria  energized  with  succinate.  Finally,  antimycin  A  at  2.5  µM  was  used  in  order  to 
completely  inhibit  of  complex  III  (building  so  called  ROX  state)  (Residual  Oxygen  consumption 
remains) in electron transfer system (ETS). ROX is the respiration due to oxidative side reactions 
remaining after application of ETS inhibitors to mitochondrial preparation(s). The value of ROX was 
measured separately for every mitochondrial sample and then ROX was subtracted from the other 
designated states (state P, state T, state E).  
3.6. Mitochondrial Parameters 
Directly, the following mitochondrial respirometry parameters were measured using oxygraph:  
￿  Leak  respiration  (State  2)—mitochondrial  respiration  in  the  presence  of  egzogenous  added 
substrates and inhibitors,  
￿  State 3 respiration (or State P)—it is the ADP stimulated respiration of isolated coupled rat heart 
mitochondria in the presence of saturating ADP and Pi concentrations, supported by succinate as 
a substrate at saturating oxygen level, 
￿  State  4  respiration  (or  State  T)—it  is  the  respiratory  state  obtained  in  isolated  rat  heart 
mitochondria after State 3, when added ADP is phosphorylated completely to ATP driven by 
electron transfer from respiratory substrates to O2. 
￿  State  E  (ETS  capacity)—it  is  a  respiratory  Electron  Transfer  System  capacity  of  rat  heart 
mitochondria  in  the  experimentally  induced  non-coupled  (fully  uncoupled)  state,  in  the 
mitochondrial preparations with succinate as a substrate. This state is induced by FCCP addition,  
￿  ROX state—induced by Antymicin A addition. 
Respiratory Control Ratio (RCR); L/E (Leak Control Ratio), P/E (Phosphorylation System Control 
Ratio) and ADP/O flux ratio were calculated according to the procedure described in [9,17]. 
￿  RCR (Respiratory Control Ratio)—is measured as State3/State 4, Int. J. Mol. Sci. 2011, 12                       
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￿  L/E ratio (Leak Control Ratio)—is measured as a ratio of “leak” respiration (State 2) to ETS 
capacity (State E), 
￿  P/E (Phosphorylation System Control Ratio)—is measured as a ratio of State 3 (State P) to ETS 
capacity (state E), 
￿  ADP/O (nmol ADP/nAtm O)—it informs how much mol of ATP is produced per mol of oxygen. 
It is calculated by measuring the decrease in oxygen concentration during the rapid burst of state 
3 (State P) respiration after adding a known amount of ADP. It is necessary to subtract the basal 
respiration  (State  2)  due  to  imperfect  coupling  and  the  recycling  of  ATP.  The  change  in 
concentration must then be multiplied by the chamber volume (2 mL). The quantity of oxygen in 
the chamber is calculated from published oxygen solubility data at the appropriate temperature.  
3.7. Statistical Analysis 
All the values from the tested animal groups (4) were expressed as a median and lower-upper 
quartile range. Data normality was checked using the Shapiro–Wilk’s test. Homogeneity of variance 
was evaluated using the Levene’s test. The statistical significance between tested groups was estimated 
using one-way ANOVA and post hoc Tukey-Kramer test for multiple comparisons (more than two 
groups). For data that showed non-homogeneity of variance, the non-parametric Kruskal-Wallis test, 
median test and post hoc all pairwise Connover–Inman test were used.  
4. Conclusions 
In summary, our present findings are the first to provide clear evidence that RAG can be used as the 
heart mitochondrial protective agent in the  chronic experimental diabetes. This study showed that 
RAG  successfully  reduces  harmful  diabetes  impact  on  mitochondrial  respiratory  maintaining  its 
activity  characteristic  for  mitochondria  isolated  from  healthy  (non-diabetic)  rats.  Although  the 
mechanisms  of  the  action  of  RAG  on  mitochondria  may  still  remain  elusive  to  some  extent,  our 
present data revealed that this agent can be used successfully under some pathological conditions 
where hyperglycaemia plays a significant role. 
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